ImmunityBio Inc (IBRX)
7.64
-0.11
(-1.42%)
USD |
NASDAQ |
May 17, 16:00
7.65
+0.01
(+0.13%)
Pre-Market: 09:03
ImmunityBio Enterprise Value: 5.808B for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 5.808B |
| May 16, 2024 | 5.877B |
| May 15, 2024 | 6.119B |
| May 14, 2024 | 6.327B |
| May 13, 2024 | 6.486B |
| May 10, 2024 | 6.133B |
| May 09, 2024 | 6.092B |
| May 08, 2024 | 5.995B |
| May 07, 2024 | 6.230B |
| May 06, 2024 | 5.919B |
| May 03, 2024 | 6.845B |
| May 02, 2024 | 6.591B |
| May 01, 2024 | 6.300B |
| April 30, 2024 | 5.927B |
| April 29, 2024 | 6.604B |
| April 26, 2024 | 5.494B |
| April 25, 2024 | 3.977B |
| April 24, 2024 | 3.781B |
| April 23, 2024 | 4.235B |
| April 22, 2024 | 3.862B |
| April 19, 2024 | 4.086B |
| April 18, 2024 | 3.842B |
| April 17, 2024 | 4.065B |
| April 16, 2024 | 3.848B |
| April 15, 2024 | 4.065B |
| Date | Value |
|---|---|
| April 12, 2024 | 3.977B |
| April 11, 2024 | 4.620B |
| April 10, 2024 | 4.553B |
| April 09, 2024 | 4.688B |
| April 08, 2024 | 4.695B |
| April 05, 2024 | 4.383B |
| April 04, 2024 | 4.322B |
| April 03, 2024 | 4.383B |
| April 02, 2024 | 4.085B |
| April 01, 2024 | 4.119B |
| March 31, 2024 | 4.153B |
| March 28, 2024 | 4.052B |
| March 27, 2024 | 4.113B |
| March 26, 2024 | 3.882B |
| March 25, 2024 | 4.082B |
| March 22, 2024 | 4.507B |
| March 21, 2024 | 4.574B |
| March 20, 2024 | 4.453B |
| March 19, 2024 | 4.076B |
| March 18, 2024 | 3.941B |
| March 15, 2024 | 3.874B |
| March 14, 2024 | 3.725B |
| March 13, 2024 | 3.824B |
| March 12, 2024 | 3.804B |
| March 11, 2024 | 3.864B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.152B
Minimum
Mar 20 2023
14.99B
Maximum
Mar 10 2021
3.247B
Average
2.698B
Median
Enterprise Value Benchmarks
| Vanda Pharmaceuticals Inc | -75.22M |
| iBio Inc | 16.77M |
| Lixte Biotechnology Holdings Inc | 5.620M |
| Abeona Therapeutics Inc | 136.95M |
| Chromocell Therapeutics Corp | 11.27M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -134.11M |
| Revenue (Quarterly) | 0.04M |
| Total Expenses (Quarterly) | 95.24M |
| EPS Diluted (Quarterly) | -0.20 |
| Profit Margin (Quarterly) | -335.3K% |
| Earnings Yield | -14.25% |
| Normalized Earnings Yield | -12.64 |